British ophthalmic equipment manufacturer Rayner has secured US Food and Drug Administration (FDA) clearance for Sophi, its Swiss-engineered phacoemulsification system.
In a media release the company said Sophi (Swiss Ophthalmology Innovation) brought a “bold new philosophy to the operating room: maximum productivity, without compromise”.
Following the FDA approval, Rayner CEO Tim Clover said: “US surgeons deserve an innovative alternative to conventional phaco technology, and Sophi delivers that.
“Clinics worldwide tell us they’re running more efficiently and cutting cost and waste, so we’re looking forward to bringing these benefits to surgeons across the US through our new team of surgical equipment specialists”.
Rayner said the device was packed with features tailored to meet the demands of office-based surgery and US hospital networks alike, such as Triple Pump Fluidics (both peristaltic and venturi), an intuitive user interface and wireless power concept.
It said Sophi was engineered for streamlined workflows and surgeons and clinical teams would benefit from faster setup, quicker patient turnover and greater mobility, without sacrificing patient safety.
Beyond performance, Rayner said Sophi was prepared for the future of sustainable ophthalmology.
A recent position paper from leading ophthalmic societies (ASCRS, ESCRS, APACRS, LATAMSCRS) estimated a 307kg reduction in discarded plastic per 1,000 cataract surgeries using Sophi’s day cassette option.
The company said it was committed to bringing this highly popular feature to the US market soon, supporting the industry’s drive to reduce surgical waste and carbon footprint.
